What is an Aptamer?
- Nucleic acid sequence selected for its ability to bind specifically to a target ligand.
- Sometimes referred to as ‘nucleic acid antibodies’.
- Aptamers have a flexible backbone which allows aptamers to wrap around small molecule targets.
- Aptamers fill the gaps left in the affinity ligands market.
- Aptamers can be generated against greater range of targets, including toxic and non-immunogenic targets which are not suitable for antibody generation.
- Aptamers are isolated using an in vitro selection approach. No animals are used at any stage during their isolation, development, refinement or downstream production. This gives them an ethical advantage in a market which is trying to steer away from animal use as far as possible.
- Security of supply and ease of production are key drivers; unlike antibodies, aptamers do not change with time
- Aptamers are readily soluble and can be stored dry; simplifying their transport as no ‘cold chain storage’ is required.
What our customers say
“We first started looking into aptamers last year as we wanted to monitor therapeutic levels In vitro. Working with Aptamer Group showed just how special aptamers really are. Their selection process is very adaptive and the team responded promptly to any questions we had. The aptamers function as required with very good binding affinity and specificity.”
Clinical Research Organisation
“After trying various alternatives we reached out to Aptamer Group to see if their selection service could help. We were initially impressed by how quickly they responded to our enquiry. We stayed in regular contact throughout the course of the project with regular updates and data to show progress. This communication really helped me feel like I was part of the work and had control the whole way through.”
Top 10 Global Pharma
“[We] collaborated with the Aptamer Group on an Innovate UK funded project in 2014. We really enjoyed working with the team at Aptamer Group and found them to be very competent scientists as well as nice people to work with. The outcome of the project is still having an influence on our business activities today. I also worked closely with Arron and David during 2016 on some internal project work and I know them to be extremely committed to the success of their business. I am sure our two businesses will collaborate again in the future.”